EcoDrugPlus

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSMPUG00000019995
Gene Symbol: CHRM1
2 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSMPUG00000004037
Gene Symbol: CHRM2
2 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSMPUG00000012712
Gene Symbol: CHRM3
2 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSMPUG00000018440
Gene Symbol: CHRM4
2 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSMPUG00000019837
Gene Symbol: CHRM5
2 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSMPUG00000010873
Gene Symbol: CHRNA3
2 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSMPUG00000008195
Gene Symbol: CHRNA4
2 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSMPUG00000014632
Gene Symbol: CHRNA7
1 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMPUG00000007148
Gene Symbol: CHRNB2
1 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSMPUG00000010868
Gene Symbol: CHRNB4
2 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSMPUG00000005588
Gene Symbol: CMA1
2 Cross references
293 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMPUG00000005558
Gene Symbol: F2R
2 Cross references
327 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).